Anemia Studies in CKD: Erythropoiesis via a Novel Prolyl hydroxylase inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)

Trial Identifier: 201771
Sponsor: GlaxoSmithKline
Collaborator:
Not applicable
Start Date: July 2019
Primary Completion Date: July 2022
Study Completion Date: July 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States, Texas Fort Worth, Texas, United States, 76104
United States, Texas Lufkin, Texas, United States, 75904
United States, Texas San Antonio, Texas, United States, 78212